# US 2008/0306007 A1 · Agents for prophylaxis or treatment of neurological related diseases and conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306007 A1
- Document ID: US20080306007A1
- Status: Published application
- Kind: A1
- Application number: 12/112,359
- Filed: 2008-04-30
- Published: 2008-12-11
- Earliest claimed: 2007-04-30
- Assignees: Newcastle Innovation Limited; Children's Medical Research Institute; The University Court of the University of Edinburgh
- Inventors: Adam McCluskey; Phillip Robinson; Michael Cousin
- Web page: https://patentgrep.com/patent/US20080306007A1

## CPC

- G01N 33/5058: {Neurological cells}
- A61K 38/46: Hydrolases (3)
- A61P 25/00: Drugs for disorders of the nervous system
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 14/4722: {G-proteins}
- C12Y 306/05005: Dynamin GTPase (3.6.5.5)
- G01N 2800/28: Neurological disorders
- G01N 2800/2821: Alzheimer
- G01N 2800/2835: Movement disorders, e.g. Parkinson, Huntington, Tourette
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Inhibitors of syndapin I binding to dynamin I (DynI) are provided. Examples include mimetics of a region of DynI including the serine residues S774 and S778 or phosphorylatable amino acids in homologous positions. Typically, the mimetics exclude or do not imitate at least one phosphorylation site provided by the serine residues or phosphorylatable amino acids. Peptide fragment inhibitors comprising or consisting of this region of DynI are also described. The inhibitors have application in the prophylaxis or treatment of neurological diseases or conditions. The inhibitors can also be used to inhibit neuronal cell vesicle trafficking and synaptic signal transmission.

## Claims

### Claim 1

An inhibitor of syndapin I binding to dynamin I (Dyn I), the inhibitor being a mimetic of a region of DynI including the serine residues S774 and S778 or phosphorylatable amino acids in homologous positions.

### Claim 2 (depends on 1)

A mimetic according to claim 1 being a mimetic of a region of Dyn I comprising amino acid sequence DynI772-784 (RRSPTSSPTPQRR) (SEQ ID No. 4) or a homologous sequence thereof.

### Claim 3 (depends on 2)

A mimetic according to claim 2 which excludes or does not imitate at least one phosphorylation site provided by S774 or S778 or phosphorylatable amino acids in homologous positions.

### Claim 4 (depends on 3)

A mimetic according to claim 3 in which at least one of S774 and S778, or at least one phosphorylatable amino acid in a homologous position to S774 or S778, is substituted for an amino acid other than a negatively charged amino acid.

### Claim 5 (depends on 4)

A mimetic according to claim 4 in which both of S774 and S778, or phosphorylatable amino acids in homologous positions, are respectively substituted for an amino acid other than a negatively charged amino acid.

### Claim 6 (depends on 5)

A mimetic according to claim 5 which has basic amino acids in positions corresponding to arginine residues R769 and R770, and basic amino acids in positions corresponding to R783 and R784.

### Claim 7 (depends on 6)

A mimetic according to claim 6 which retains at least one of R769 and R770 and at least one of R783 and R784, or has arginine amino acid residues in homologous positions to at least one of R769 and R770 and at least one of R783 and R784.

### Claim 8 (depends on 2)

A mimetic according to claim 2 having an amino acid sequence identity to DynI772-784 (RRSPTSSPTPQRR) (SEQ ID No. 4) of 60% or greater.

### Claim 9 (depends on 8)

A mimetic according to claim 8 being a mimetic of the amino acid sequence consisting of DynI772-784 (RRSPTSSPTPQRR) (SEQ ID No. 4).

### Claim 10 (depends on 1)

A mimetic according to claim 1 being a peptide mimetic up to 40 amino acids in length.

### Claim 11 (depends on 1)

A mimetic according to claim 1 adapted to pass across outer cell membrane into neurons or being coupled to a facilitator moiety for facilitating passage or translocation of the mimetic into neurons.

### Claim 12 (depends on 11)

A mimetic according to claim 11 coupled to a penetratin amino acid sequence for facilitating passage of the mimetic into neurons.

### Claim 13

A pharmaceutical composition comprising at least one inhibitor of syndapin I binding to dynamin I (Dyn I) together with a pharmaceutically acceptable carrier, the inhibitor being a mimetic of a region of DynI including the serine residues S774 and S778 or phosphorylatable amino acids in homologous positions.

### Claim 14

A method for prophylaxis or treatment of a neurological disease or condition in an individual, comprising administering to the individual an effective amount of an inhibitor of syndapin I binding to dynamin I (Dyn I), the inhibitor being a fragment of a region of DynI including the serine residues S774 and S778 or phosphorylatable amino acids in homologous positions, or a mimetic of the region of Dyn I.

### Claim 15 (depends on 14)

A method according to claim 14, the inhibitor being a mimetic of a region of Dyn I comprising amino acid sequence DynI772-784 (RRSPTSSPTPQRR) (SEQ ID No. 4) or a homologous sequence thereof.

### Claim 16 (depends on 15)

A method according to claim 15 wherein the mimetic excludes or does not imitate at least one phosphorylation site provided by S774 or S778 or phosphorylatable amino acids in homologous positions.

### Claim 17 (depends on 16)

A mimetic according to claim 16 in which at least one of S774 and S778, or at least one phosphorylatable amino acid in a homologous position to S774 or S778, is substituted for an amino acid other than a negatively charged amino acid.

### Claim 18 (depends on 17)

A mimetic according to claim 17 in which both of S774 and S778 or phosphorylatable amino acids in homologous positions are respectively substituted for an amino acid other than a negatively charged amino acid.

### Claim 19 (depends on 16)

A mimetic according to claim 16 which has basic amino acids in positions corresponding to arginine residues R769 and R770, and basic amino acids in positions corresponding to R783 and R784.

### Claim 20 (depends on 16)

A mimetic according to claim 16 which retains at least one of R769 and R770 and at least one of R783 and R784, or has arginine amino acid residues in homologous positions to at least one of R769 and R770 and at least one of R783 and R784.

### Claim 21 (depends on 15)

A mimetic according to claim 15 having an amino acid sequence identity to DynI772-784 (RRSPTSSPTPQRR) (SEQ ID No. 4) of 60% or greater.

### Claim 22 (depends on 21)

A mimetic according to claim 21 being a mimetic of the amino acid sequence consisting of DynI772-784 (RRSPTSSPTPQRR) (SEQ ID No. 4).

### Claim 23 (depends on 14)

A method according to claim 14 wherein the mimetic is a peptide mimetic up to 40 amino acids in length.

### Claim 24 (depends on 14)

A method according to claim 14 wherein the mimetic is adapted to pass across outer cell membrane into neurons or is coupled to a facilitator moiety which facilitates passage or translocation of the mimetic into neurons.

### Claim 25 (depends on 14)

A method according to claim 14 wherein the neurological disease or condition is selected from the group consisting of diseases and conditions associated with cell vesicle trafficking, diseases and conditions associated with synaptic signal transmission, psychotic and psychiatric conditions, neurodegenerative diseases, epilepsy, neuropathic pain, β-amyloid associated diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease, Lewis body dementias and neuroparalytic diseases.

### Claim 26 (depends on 25)

A method according to claim 25 wherein the neurological disease or condition is epilepsy.

### Claim 27

A method for prophylaxis or treatment of a neurological disease or condition in a mammal, comprising administering to the mammal an effective amount of an inhibitor of syndapin I binding to dynamin I.

### Claim 28

A method for prophylaxis or treatment of epilepsy in a mammal, comprising administering to the mammal an effective amount of an inhibitor of syndapin I binding to dynamin I.

### Claim 29

A method for inhibiting synaptic signal transmission, comprising treating a neuron with an effective amount of an inhibitor of syndapin I binding to dynamin I.

### Claim 30

A method for inhibiting synaptic vesicle endocytosis, comprising treating a neuron with an effective amount of an inhibitor of syndapin I binding to dynamin I.

### Claim 31

A method for screening a test compound for capacity to inhibit interaction of dynamin I (DynI) with syndapin I, comprising:
providing the test compound to be screened;
incubating the test compound with DynI or a molecule substituting for DynI in the presence of a syndapin I or a molecule substituting for syndapin I; and
determining whether the compound inhibits the interaction of DynI with syndapin I.

### Claim 32 (depends on 31)

A method according to claim 31 wherein the determination of whether the test compound inhibits the interaction of Dyn I with syndapin I involves determining whether or not synaptic vesicle endocytosis is inhibited by the compound.
